Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 2

Tislelizumab With Chemotherapy and Artery Chemoembolization for Lung Cancer That Cannot Be Operated On

Tests tislelizumab, chemotherapy and chemoembolization in adults with non-small cell lung cancer unsuitable for surgery.

Key facts

Who runs it
Sichuan Cancer Hospital and Research Institute
Where
Chengdu, ChinaSee the site
Trial code
Registry title
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
Status
Not yet recruiting
Phase
Phase 2
People taking part
39 people, planned
Started
1 May 2026
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • Tislelizumab
  • Intravenous Chemotherapy
  • Bronchial Artery Chemoembolization (BACE)
Record updated
1 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed non-small cell lung cancer, stage IIIA-IIIB, that cannot be removed by surgery at the start.

Age
18 to 80 years
Sex
Women and men can join.
Disease stage
Non-small cell lung cancer, stage IIIA-IIIB (9th edition TNM staging). Doctors must judge it initially unresectable. At least 1 measurable lesion in the lung.
Earlier treatment
No earlier treatment for the lung cancer, including radiotherapy or interventional therapy.
Biomarker or test result
No known EGFR mutations, ALK rearrangements, ROS1 rearrangements or MET exon 14 skipping changes. Tumor tissue must be provided for pathology, molecular testing and PD-L1 testing.

Main reasons for not taking part

  • Cancer has spread to distant organs
  • Another cancer within the past 5 years
  • Active autoimmune disease, or past autoimmune disease needing systemic treatment
  • Interstitial lung disease, non-infectious pneumonitis or COPD
  • Severe chronic or active infection needing systemic treatment, including active tuberculosis

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age 18 to 80 years
  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
  • Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system
  • Initially unresectable disease as determined by multidisciplinary team (MDT) assessment
  • At least 1 measurable intrapulmonary lesion according to RECIST version 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Forced expiratory volume in the first second (FEV1) > 1.0 L and > 40% of predicted normal value
  • Estimated life expectancy of at least 3 months
  • Adequate organ function
  • Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment
  • Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab
  • Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab
  • Ability to understand and willingness to sign a written informed consent form

Who cannot take part

  • Prior local therapy for NSCLC, including radiotherapy or interventional therapy
  • Major surgery requiring general anesthesia within 4 weeks before first dose
  • History of another malignancy within the past 5 years
  • Active autoimmune disease or history of autoimmune disease requiring systemic treatment
  • Known allergy to any study drug or excipient
  • Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment
  • Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis
  • Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk
  • Psychiatric illness or history of psychotropic drug abuse that may compromise study participation
  • Any condition judged by the investigator to make the patient unsuitable for the study
  • Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations
  • Distant organ metastasis
  • Participation in another interventional therapeutic clinical study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • Sichuan Cancer Hospital and Research InstituteChengdu, ChinaContact: Guohui XuNo longer taking part

About the trial

What the trial wants to find out

The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:

Read full original descriptionShow less

* What is the 1-year event-free survival (EFS) rate with this treatment? * Can this treatment improve tumor response and the chance of curative-intent resection? * What adverse events occur during treatment?

Participants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.

The group in the trial

  • Tislelizumab Plus Chemotherapy and BACETreatment being tested

    Participants receive tislelizumab, intravenous chemotherapy, and bronchial artery chemoembolization (BACE) as conversion therapy. Tislelizumab 200 mg is administered intravenously on Day 0 of each 21-day cycle. On Day 1, participants receive intravenous chemotherapy (albumin-bound paclitaxel for lung squamous cell carcinoma or pemetrexed for lung adenocarcinoma) and BACE with intra-arterial carboplatin plus 300-500 μm blank microspheres. Conversion treatment is given for up to 4 cycles. The number of BACE procedures ranges from 1 to 4 and is determined by tumor response and multidisciplinary team assessment. Participants who become resectable may undergo surgery followed by protocol-defined postoperative treatment. Participants who remain unresectable after 4 cycles may receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation.

    Treatment: Tislelizumab, Intravenous Chemotherapy, and Bronchial Artery Chemoembolization (BACE)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)
Plain-language title
Tislelizumab With Chemotherapy and Artery Chemoembolization for Lung Cancer That Cannot Be Operated OnGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07561983, who can take part
Record updated
1 May 2026